Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
H.B. Fuller Exec VP Nathan D. Weaver sells 9,561 shares for $593,271.08

H.B. Fuller Exec VP Nathan D. Weaver sells 9,561 shares for $593,271.08

ReutersReuters2026/08/12 16:23
  • H.B. Fuller Exec VP, Business Transform. Nathan D. Weaver sold 9,561 common shares on Aug. 11, 2026 at USD 62.06.
  • Weaver exercised employee stock options for 9,561 shares at USD 50.1 and USD 53.57.
  • Directly held common shares totaled 11,739 following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H.B. Fuller Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001225208-26-007076), on August 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas